Get the Stockscreener App
3.20
0.95%
0.03
After Hours:
3.20
Aclarion Inc stock is traded at $3.20, with a volume of 38,390.
It is up +0.95% in the last 24 hours and down -3.90% over the past month.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
See More
Previous Close:
$3.17
Open:
$3.1
24h Volume:
38,390
Relative Volume:
0.25
Market Cap:
$7.30M
Revenue:
$75,700
Net Income/Loss:
$-7.23M
P/E Ratio:
-0.186
EPS:
-17.2081
Net Cash Flow:
$-7.37M
1W Performance:
-10.36%
1M Performance:
-3.90%
6M Performance:
-64.84%
1Y Performance:
-64.99%
1-Day Range:
$3.06
$3.27
1-Week Range:
$2.97
$3.94
52-Week Range:
$2.3401
$12.03
Aclarion Inc Stock (ACON) Company Profile
Name
Aclarion Inc
Sector
Industry
Phone
833 275 2266
Address
8181 ARISTA PLACE, BROOMFIELD
Compare ACON vs VEEV, TEM, BTSG, HQY, WAY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACON
Aclarion Inc
|
3.20 | 7.24M | 75,700 | -7.23M | -7.37M | -17.21 |
VEEV
Veeva Systems Inc
|
167.30 | 25.98B | 3.20B | 908.91M | 1.39B | 5.4168 |
TEM
Tempus Ai Inc
|
56.41 | 8.89B | 1.27B | -245.03M | -245.36M | -1.4071 |
BTSG
Brightspring Health Services Inc
|
46.01 | 8.89B | 12.91B | 104.80M | 394.69M | 0.8769 |
HQY
Healthequity Inc
|
83.67 | 6.87B | 1.31B | 215.20M | 408.32M | 2.4627 |
WAY
Waystar Holding Corp
|
24.68 | 4.30B | 1.10B | 112.09M | 283.19M | 0.6096 |
Aclarion Inc Stock (ACON) Latest News
Aclarion's AI Platform Nociscan Wins Pinnacle Award, Validating Approach to Chronic Low Back Pain Diagnosis - citybuzz -
AI tool for chronic back pain earns Aclarion a second health tech award - Stock Titan
Aclarion (ACON) price target decreased by 69.57% to 7.14 - MSN
Take Profit: Will Opendoor Technologies Inc outperform the market in YEAR2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
Aclarion Announces Agreement with Weill Cornell Medicine - Bitget
Aclarion establishes agreement with Weill Cornell Medicine By Investing.com - Investing.com Australia
Aclarion Partners with Weill Cornell Medicine to Expand Nociscan Use in Spine Pain Research - citybuzz -
Aclarion establishes agreement with Weill Cornell Medicine - Investing.com
Weill Cornell spine study adds Aclarion tool for chronic back pain - Stock Titan
Trading Action: How does Aclarion Inc compare to its peers2026 Analyst Calls & Capital Efficiency Focused Ideas - baoquankhu1.vn
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video - marketscreener.com
Aclarion says one London clinic has used its back-pain scan nearly 100 times - Stock Titan
Why Aclarion Inc. stock could rally in 20262026 Short Interest & Verified Stock Trade Ideas - bollywoodhelpline.com
Aclarion (ACON) to Release Quarterly Earnings on Tuesday - Defense World
Chipmakers Recap: Will Aclarion Inc Equity Warrant outperform tech stocksMarket Activity Report & Expert Verified Movement Alerts - baoquankhu1.vn
Street Watch: Will Aclarion Inc Equity Warrant outperform tech stocksGap Up & Low Risk Investment Opportunities - baoquankhu1.vn
Aclarion (NASDAQ: ACON) seeks stockholder approval to expand equity plan to 500,000 shares - Stock Titan
ACON Should I Buy - Intellectia AI
Aclarion Inc Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - Mint
US Market Wrap: Will Aclarion Inc Equity Warrant outperform tech stocks2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Is Aclarion Inc Equity Warrant stock a good dividend stock2026 Momentum & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Macro: How does Aclarion Inc Equity Warrant correlate with Nasdaq2026 Growth vs Value & Fast Moving Stock Watchlists - baoquankhu1.vn
SEG Opportunity Fund (ACON) discloses 244,043 shares, 9.98% of Aclarion - Stock Titan
Aclarion (ACON): Analyst Lowers Price Target While Maintaining B - GuruFocus
Macro Review: Should I hold or sell Aclarion Inc Equity Warrant now2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. - Bitget
Investment Review: Is Aclarion Inc. still a buy after recent gains2026 Review & Stepwise Trade Signal Guides - baoquankhu1.vn
Targets Report: Is Aclarion Inc still a buy after recent gainsPortfolio Update Summary & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Aclarion, Inc. Adopts One-Year Stockholder Rights Plan to Protect Shareholder Value and Prevent Hostile Takeovers - Minichart
Aclarion adopts one-year stockholder rights plan By Investing.com - Investing.com India
Aclarion Adopts One-Year Stockholder Rights Protection Plan - TipRanks
Aclarion (NASDAQ: ACON) sets 10% trigger in one-year rights plan - Stock Titan
Aclarion adopts one-year stockholder rights plan - Investing.com
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan - The Manila Times
Aclarion installs 1-year takeover defense, keeps door open to fair bids - Stock Titan
Shareholder Letter From Chief Executive Officer Brent Ness - 富途牛牛
Aclarion, Inc. Pursues Insurance Reimbursement Initiatives and Reports Strong Momentum Leading into 2026 - Quiver Quantitative
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts - Bluefield Daily Telegraph
Aclarion : Shareholder Letter from Chief Executive Officer Brent Ness - MarketScreener
Aclarion, Inc. Revolutionizes Low Back Pain Diagnosis with MR Spectroscopy and AI-Powered NOCISCAN Platform 798083 - Minichart
Published on: 2026-03-19 07:53:44 - baoquankhu1.vn
Aclarion (NASDAQ: ACON) expands NOCISCAN spine diagnostics and AI plans - Stock Titan
Aclarion 10-K: Revenue $0.076M, EPS (13.61) — Annual Report Highlights - tradingview.com
ACON: Revenue up 65.6% to $75.7K; net loss $7.2M; $22.6M raised in 2025, $10.4M in 2026 - tradingview.com
Aclarion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Published on: 2026-03-19 06:54:42 - baoquankhu1.vn
Aclarion to Present at ROTH Conference, Showcasing Nociscan Technology for Chronic Back Pain Diagnosis - citybuzz -
Is Aclarion Inc Equity Warrant still a buy after recent gainsQuarterly Profit Report & Safe Entry Trade Reports - baoquankhu1.vn
Aclarion, Inc. to Engage with Investors at the 38th Annual ROTH Conference Regarding Nociscan Advancements - Quiver Quantitative
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet - Bitget
Aclarion Inc Stock (ACON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):